Cumulus Neuroscience to Present Data at 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

July 7, 2023
  • Interim analysis of CNS-102 study suggests that the Cumulus Neuroassessment Platform can identify cognitive defects among, and is feasible for in-home use by, patients living with Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTD)
  • Poster presentations scheduled Wednesday, July 12, at 6PM and Thursday, July 13, at 5:50PM at the European Network to Cure ALS (ENCALS) Annual Meeting in Barcelona, Spain

BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 6, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, will present interim data from their CNS-102 feasibility study at the European Network to Cure ALS Annual Meeting (ENCALS) in Barcelona, Spain. Using the proprietary Cumulus Neuroassessment Platform to gather data via repeated at-home sampling, the study is being conducted in collaboration with the Trinity Biomedical Science Institute.

Titled “Patient and technical feasibility of real-world sampling of cognition and functional neurophysiology in Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD),” the poster was accepted by the ENCALS Program Committee as part of its annual meeting focused on developing a European ALS research network.

“People with ALS or FTD often experience cognitive and behavioral changes, along with physical symptoms – yet detection can be challenging as a result of barriers that many participants can face during in-office clinical visits, such as fatigue, white coat syndrome and test anxiety,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. “We are encouraged by the interim data analysis from our CNS-102 feasibility study, which confirms that patients living with ALS and FTD are capable and willing to participate in home-based studies with intensive repeated sampling protocols. We are deeply grateful to the patients, caregivers and collaborators who dedicate their time with the hope of better understanding these life-changing neurodegenerative diseases and accelerate necessary and needed new treatments.”

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. In ALS, the motor neurons responsible for controlling voluntary muscle movement degenerate and die, leading to a gradual loss of muscle control, affecting the ability to speak, eat, move, and eventually breathe. Currently, there is no known cure for ALS, and the disease is typically fatal.[i] FTD (Frontotemporal Dementia) is a rare group of degenerative brain disorders that primarily affect the frontal and temporal lobes of the brain, leading to progressive loss of language, behavioral changes, and difficulty with decision-making and emotional regulation. It often affects people under the age of 65 and can be challenging to diagnose due to its varied symptoms. There is currently no cure for either of these conditions and treatment is aimed at managing symptoms and improving quality of life.[ii] Ongoing research is needed to develop effective treatments for both conditions.

Cumulus poster presentation details are as follows:

  • Poster: “Patient and technical feasibility of real-world sampling of cognition and functional neurophysiology in ALS and FTD”
  • Poster Session 1: Wednesday, July 12, 2023, at 6PM-7:30PM (CEST)
  • Poster Session 2: Thursday, July 13, 2023, at 5:50PM-7:00PM (CEST)
  • Poster #: 286

A second, independent poster utilizing and highlighting Cumulus Platform data will be presented by primary investigator Orla Hardiman’s group at the Trinity Biomedical Science Institute titled, “Longitudinal cognitive assessment using the Cumulus home-based EEG platform in ALS and FTD.”

  • Poster #: 272

Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit

[i] Naqvi E. Als facts and Statistics. ALS News Today. March 20, 2019. Accessed July 5, 2023.

[ii] Frontotemporal Dementia (FTD). Alzheimer’s Society. June 1, 2023. Accessed July 5, 2023.

Notes to Editors

With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.

Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient’s home – all with an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.

The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.